Literature DB >> 15800765

[Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].

M Schmücking1, R P Baum, R Bonnet, K Junker, K-M Müller.   

Abstract

UNLABELLED: CT cannot provide useful information in a timely manner after neoadjuvant treatment. To evaluate the role of (18)F FDG PET after neoadjuvant chemoradiation for early therapy response and its effect on survival as compared to histopathologic tumor response, findings in 32 patients were analyzed prospectively in an ongoing multicenter trial (LUCAS-MD). INCLUSION CRITERIA: histologically confirmed NSCLC stage IIIA/IIIB. Neoadjuvant treatment: 2-3 cycles with paclitaxel/carboplatin and a block of chemoradiation followed by surgery. Pretherapeutic staging: PET scan in addition to a spiral CT and/or MRI. Second PET scan after completion of neoadjuvant therapy prior to surgery. Documentation of lymph node involvement. Assessment of SUV and the metabolic tumor index for primary tumor and metastatic lymph nodes. Image fusion of PET with CT data followed by molecular radiation treatment planning. Evaluation of histologic regression grade and correlation with PET for primary tumor and each lymph node location. All patients (10/32) with complete response in lymph node metastases detected by PET prior to surgery, had no vital tumor cells (i.e. histologic regression grade/RG III, sensitivity 100%). In primary tumors showing complete response, the RG was IIb or III, in one patient IIa (false negative in PET). False positive findings in PET are due to inflammation (5 patients, histologically confirmed). Univariate analyses: actuarial tumor-specific survival for complete metabolic remission vs. incomplete remission after 24 months: 76 vs. 20% (p=0,0079); for RG III/IIb vs. RG IIa/I after 24 months: 63 vs. 36% (p=0,0123).(18)F FDG PET precedes CT in measuring the tumor response and may predict (long term) therapeutic outcome in stage III NSCLC. Histologic regression grade correlates well with metabolic remission as detected by PET.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800765     DOI: 10.1007/s00292-005-0758-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  20 in total

1.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.

Authors:  K Junker; M Thomas; K Schulmann; F Klinke; U Bosse; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.

Authors:  J F Vansteenkiste; S G Stroobants; P R De Leyn; P J Dupont; E K Verbeken
Journal:  Ann Oncol       Date:  1998-11       Impact factor: 32.976

3.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Authors:  J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong
Journal:  Lung Cancer       Date:  1998-07       Impact factor: 5.705

4.  Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

Authors:  V W Rusch; D J Giroux; M J Kraut; J Crowley; M Hazuka; D Johnson; M Goldberg; F Detterbeck; F Shepherd; R Burkes; T Winton; C Deschamps; R Livingston; D Gandara
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

5.  Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer.

Authors:  M Thomas; C Rübe; M Semik; M von Eiff; L Freitag; H N Macha; W Wagner; F Klinke; H H Scheld; N Willich; W E Berdel; K Junker
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

6.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning.

Authors:  P Giraud; M Antoine; A Larrouy; B Milleron; P Callard; Y De Rycke; M F Carette; J C Rosenwald; J M Cosset; M Housset; E Touboul
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-11-01       Impact factor: 7.038

7.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

Authors:  J F Vansteenkiste; S G Stroobants; P R De Leyn; P J Dupont; J Bogaert; A Maes; G J Deneffe; K L Nackaerts; J A Verschakelen; T E Lerut; L A Mortelmans; M G Demedts
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

Review 8.  [Pathology, classification, and staging of malignant lung tumors].

Authors:  K-M Müller; T Wiethege
Journal:  Radiologe       Date:  2004-05       Impact factor: 0.635

9.  Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.

Authors:  B Herse; H Dalichau; B Wörmann; B Hemmerlein; H Schmidberger; C F Hess; P Hannemann; C P Criée; W Hiddemann; F Griesinger
Journal:  Thorac Cardiovasc Surg       Date:  1998-10       Impact factor: 1.827

10.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

View more
  5 in total

1.  Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT.

Authors:  Ah Young Lee; Su Jung Choi; Kyung Pyo Jung; Ji Sun Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2013-11-06

2.  Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease.

Authors:  Young-Sil An; Joo Sung Sun; Kyung Joo Park; Sung Chul Hwang; Kwang Joo Park; Seung Soo Sheen; Sungsoo Lee; Kyi Beom Lee; Joon-Kee Yoon
Journal:  Lung       Date:  2008-08-01       Impact factor: 2.584

3.  Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

Authors:  William N William; Apar Pataer; Neda Kalhor; Arlene M Correa; David C Rice; Ignacio I Wistuba; John Heymach; J Jack Lee; Edward S Kim; Reginald Munden; Kathryn A Gold; Vassiliki Papadimitrakopoulou; Stephen G Swisher; Jeremy J Erasmus
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

4.  18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.

Authors:  Irene A Burger; Ruben Casanova; Seraina Steiger; Lars Husmann; Paul Stolzmann; Martin W Huellner; Alessandra Curioni; Sven Hillinger; C Ross Schmidtlein; Alex Soltermann
Journal:  J Nucl Med       Date:  2016-01-28       Impact factor: 10.057

5.  Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.

Authors:  Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Thomas Krohn; Hans J Kaiser; Sven Stanzel; Christian Breuer; Branka Asadpour; Axel Schmachtenberg; Michael J Eble
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.